Moore Capital Management’s Arcus Biosciences RCUS Stock Holding History

Moore Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-40,000	Closed	-$812K	–	580
2023 Q2	$812K	Buy	+40,000	New	+$762K	0.01%	321
2021 Q3	–	Sell	-25,000	Closed	-$687K	–	857
2021 Q2	$687K	Hold	25,000	–	–	0.01%	552
2021 Q1	$702K	Sell	25,000 -10,000	-29%	-$348K	0.01%	529
2020 Q4	$909K	Hold	35,000	–	–	0.01%	419
2020 Q3	$600K	Hold	35,000	–	–	0.01%	315
2020 Q2	$866K	Buy	+35,000	New	+$945K	0.02%	214

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Moore Capital Management's RCUS Position: Q3 2023 in Review

Moore Capital Management sold out of Arcus Biosciences (RCUS) in Q3 2023, closing a stake of 40,000 shares — an estimated $812K sold.

Moore Capital Management first reported a position in RCUS in Q2 2020 and held it in 6 quarters. The position peaked at $909K in Q4 2020. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2023.

Moore Capital Management reported no remaining Arcus Biosciences position as of Q3 2023 after selling out during the quarter.
Moore Capital Management sold 40,000 Arcus Biosciences shares in Q3 2023, an estimated $812K.
Moore Capital Management first reported a position in Arcus Biosciences in Q2 2020 and held it in 6 quarters.
Moore Capital Management's Arcus Biosciences position peaked at $909K in Q4 2020.
187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2023.

Based on Moore Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.